Hevascol (Ethyl Esters Of Iodised Fatty Acids From Poppyseed Oil)

Hevascol is employed in specific medical settings where intra‑arterial or intralymphatic delivery of lipid‑based agents is required.

• Vascular imaging procedures to enhance arterial visualization.
• Lymphatic mapping during oncologic surgery.
• Adjunct in selective arterial embolization.
• Experimental studies of fatty‑acid metabolism in localized tissues.
• Supportive role in certain interventional radiology protocols.

• Ethyl esters of iodised fatty acids from poppyseed oil are lipophilic molecules that integrate into plasma membranes and local vascular or lymphatic structures. The iodinated fatty‑acid backbone provides radiodensity, allowing the compound to act as a contrast medium that highlights vessels or lymphatic channels during imaging. Their esterified form facilitates rapid distribution within the targeted compartment while minimizing systemic exposure.

Adverse reactions to Hevascol may vary in frequency and severity.

Common

• Mild injection site discomfort or erythema.
• Transient headache.
• Nausea or mild gastrointestinal upset.
• Temporary flushing or warmth sensation.
• Minor changes in blood pressure that resolve spontaneously.

Serious

• Allergic hypersensitivity reactions, including rash or angioedema.
• Severe vasospasm at the injection site.
• Acute renal impairment in susceptible individuals.
• Pulmonary embolism if inadvertently introduced into the venous system.
• Significant hemorrhage related to vascular injury.

When considering Hevascol, clinicians should evaluate patient-specific factors and procedural context.

• Verify absence of known iodine or poppyseed oil allergy before administration.
• Assess renal function, as iodinated agents may affect kidney performance.
• Use caution in patients with coagulation disorders or on anticoagulant therapy.
• Monitor vital signs during and after intra‑arterial or intralymphatic injection.
• Ensure proper catheter placement to avoid extravasation.
• Document any prior adverse reactions to similar lipid‑based contrast agents.
• Consider alternative imaging methods for pregnant or lactating individuals.

Hevascol may interact with other substances administered during interventional procedures.

Avoid

• Concurrent use of high‑dose iodinated contrast agents, which can increase iodine load.
• Administration of potent vasoconstrictors that may exacerbate vascular spasm.
• Co‑administration with nephrotoxic drugs in patients with compromised renal function.

Use with caution

• Anticoagulants or antiplatelet agents, due to potential bleeding risk at the injection site.
• Beta‑blockers, as they may influence hemodynamic responses.
• Diuretics, which could affect fluid balance and contrast distribution.
• Sedatives or analgesics that mask early signs of adverse reactions.